Shidlovski Ocular Therapeutix, Inc. (NASDAQ:OCUL) is a biopharmaceutical company developing innovative eye treatment therapies. OCUL already offers a commercial product called Dextenza for post-surgical ocular inflammation and pain and ocular itching due to allergic conjunctivitis. The drug is a market success with a net product revenue of $57.9 million in 2023. OCUL's pipeline includes Axpaxli, an axitinib intravitreal implant in phase 3 trials for wet age-related macular degeneration (wet AMD) and phase 1 ...